Total submissions: 6
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV001088215 | SCV005088968 | likely pathogenic | Mucopolysaccharidosis, MPS-II | 2024-06-07 | criteria provided, single submitter | literature only | Absent from controls (or at low frequency) in gnomAD database (PM2_Moderate), Missense variant in a gene with a low rate of benign missense variation (PP2_Supporting), Multiple lines of computational evidence support a deleterious effect (PP3_Supporting), Patient’s phenotype or family history highly specific for the disease (PP4_Strong) |
| Revvity Omics, |
RCV001088215 | SCV004235541 | uncertain significance | Mucopolysaccharidosis, MPS-II | 2023-08-15 | criteria provided, single submitter | clinical testing | |
| Genome- |
RCV001088215 | SCV002014459 | uncertain significance | Mucopolysaccharidosis, MPS-II | 2021-09-05 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV001088215 | SCV000753284 | benign | Mucopolysaccharidosis, MPS-II | 2024-08-13 | criteria provided, single submitter | clinical testing | |
| Eurofins Ntd Llc |
RCV000353621 | SCV000340484 | uncertain significance | not provided | 2016-03-14 | criteria provided, single submitter | clinical testing | |
| Natera, |
RCV001833368 | SCV002084496 | likely benign | Mucopolysaccharidosis, MPS-III-A | 2020-01-15 | no assertion criteria provided | clinical testing |